Your AI-Trained Oncology Knowledge Connection!
Michael Birrer, MD, PhD, professor of medicine, Harvard Medical School, director, Gillette Center for Gynecologic Oncology, Massachusetts General Hospital, explains how the endpoints of progression-free survival (PFS) and overall survival (OS) are holding back the approval of drugs for patients with ovarian cancer.
Viktor Grünwald, MD, PhD, an attending physician at the Hannover Medical School, discusses tumor remission in patients with renal cell carcinoma (RCC).
Debu Tripathy, MD, co-leader, Women's Cancer Program, Norris Comprehensive Cancer Center, University of Southern California, discusses integrative oncology
Alan P. Venook, MD, a professor in the Department of Medicine (Hematology/Oncology) at the University of California, San Francisco, discusses the need for collaboration in cancer research.
Jeffrey S. Weber, MD, PhD, medical oncologist, Department of Cutaneous Oncology, director, Donald A. Adam Comprehensive Melanoma Research Center, Moffitt Cancer Center, discusses testing for genetic mutations in patients with melanoma.
Hope S. Rugo, MD, professor of medicine and director of breast oncology and clinical trials education at the University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses new guidelines for the treatment of patients with metastatic breast cancer.
Mark A. Morgan, MD, professor of obstetrics and gynecology, University of Pennsylvania, director, Gynecology Oncology for University of Pennsylvania Health Systems, discusses the role of robotic surgery in gynecologic cancer.
Anthony M. Magliocco, MD, chair of pathology, executive director of esoteric labs at Moffitt Cancer Center, discusses the role of the pathologist in the treatment of a patient with melanoma.
Daniel J. George, MD, director, GU Oncology, Duke Cancer Institute, discusses the use of sunitinib to treat patients with renal cell carcinoma (RCC).
Robert A. Burger, MD, FACOG, FACS, Professor, Department of Surgical Oncology, Director, Women's Cancer Center, Fox Chase Cancer Center, discusses the use of bevacizumab in patients with ovarian cancer.
Paul Ruff, MD, director of Medical Oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses treating elderly patients with colorectal cancer with aflibercept.
Corey J. Langer, MD, professor of medicine, hematology/oncology division, University of Pennsylvania, Abramson Cancer Center, discusses the treatment of patients with early stage lung cancer.
Omid Hamid, MD, discusses using immune therapy to treat patients with melanoma.
D. Ross Camidge, MD, PhD, director, Thoracic Oncology Clinical Program, University of Colorado Cancer Center, discusses the updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies.
James "Tate" T. Thigpen, MD, Professor of Medicine, Director, Division of Medical Oncology, University of Mississippi School of Medicine, discusses the comparison of treatment options in ovarian cancer.
Paul Ruff, MD, director of medical oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses the analysis of prior bevacizumab in the VELOUR trial in patients with metastatic colorectal cancer.
Ragini Kudchadkar, MD, assistant professor, medical oncology, Moffitt Cancer Center, discusses the benefits of combining BRAF and MEK inhibitors when treating melanoma.
David P. Carbone, MD, PhD, a professor in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, discusses potential biomarkers in lung cancer.
Jo Anne Zujewski, MD, head, breast cancer therapeutics, cancer therapy evaluation program, National Cancer Institute (NCI), discusses the development of drugs to treat patients with breast cancer.
Maurie Markman, MD, from the Cancer Treatment Centers of America, discusses the discovery of mutations and targets in ovarian cancer and the current progress being made in the development of a "breakthrough" agent for ovarian cancer.
Clifford A. Hudis, MD, ASCO president, chief, Breast Cancer Medicine Service, Attending Physician, Memorial Sloan-Kettering Cancer Center, discusses his optimism surrounding immunotherapy for cancer care.
Silvia Novello, MD, PhD, assistant professor, Thoracic Oncology Unit, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses some of the "gray areas" that require more research for the treatment of patients with lung cancer.
Julie R. Brahmer, MD, from Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, discusses the management of adverse events (AEs) from treatment with immunotherapies.
Torsten O. Nielsen, MD, PhD, FRCPC, a professor of pathology at the University of British Columbia, discusses the pros and cons of using the Ki67 as a prognostic marker in breast cancer.
Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the design of a phase II study of selumetinib versus temozolomide in uveal melanoma with GNAQ/GNA11 mutations.
Harvey I. Pass, MD, Stephen E. Banner Professor of Thoracic Oncology, Vice-Chair Research, Department of Cardiothoracic Surgery, Division Chief, General Thoracic Surgery, NYU Langone Medical Center, discusses blood-based markers in lung cancer.
Kathy S. Albain, MD, medical oncologist, Loyola University Chicago, professor, Stritch School of Medicine, director, Breast Clinical Research Program, Thoracic Oncology Research Program, Cardinal Bernardin Cancer Center, discusses staging versus biology in breast cancer.
Jeffrey A. Sosman, MD, professor of medicine, Director, Melanoma and Tumor Immunotherapy Program, Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, describes the mechanism of action of ipilimumab in patients with melanoma.
Edith Mitchell, MD, FACP, clinical professor, director, Center to Eliminate Cancer Disparities Program Leader, Thomas Jefferson University, discusses an analysis of the VELOUR trial.
Giorgio V. Scagliotti, MD, PhD, head, Thoracic Oncology Unit, Department of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Orbassano, Italy, discusses treating epidermal growth factor receptor- (EGFR) mutated tumors with afatinib.